Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss

References

• BoyleWJSimonetWSLaceyDLOsteoclast differentiation and activationNature2003423693733734212748652
   PubMed Web of Science ®Google Scholar
• CompstonJOsteoporosis: social and economic impactRadiol Clin North Am201048347748220609886
   PubMed Web of Science ®Google Scholar
• RogersAEastellRCirculating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessmentJ Clin Endocrinol Metab200590116323633116105967
   PubMed Web of Science ®Google Scholar
• KearnsAEKhoslaSKostenuikPJReceptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and diseaseEndocr Rev200829215519218057140
   PubMed Web of Science ®Google Scholar
• KhoslaSMinireview: the OPG/RANKL/RANK systemEndocrinology2001142125050505511713196
   PubMed Web of Science ®Google Scholar
• LaceyDLTimmsETanHLOsteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activationCell19989321651769568710
   PubMed Web of Science ®Google Scholar
• SchoppetMPreissnerKTHofbauerLCRANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular functionArterioscler Thromb Vasc Biol200222454955311950689
   PubMed Web of Science ®Google Scholar
• KongYYYoshidaHSarosiIOPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesisNature199939767173153239950424
   PubMed Web of Science ®Google Scholar
• NakagawaNKinosakiMYamaguchiKRANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesisBiochem Biophys Res Commun199825323954009878548
   PubMed Web of Science ®Google Scholar
• LiuCWalterTSHuangPStructural and functional insights of RANKL-RANK interaction and signalingJ Immunol2010184126910691920483727
   PubMed Web of Science ®Google Scholar
• BordSIrelandDCBeavanSRCompstonJEThe effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblastsBone200332213614112633785
   PubMed Web of Science ®Google Scholar
• KhoslaSAtkinsonEJDunstanCRO’FallonWMEffect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly menJ Clin Endocrinol Metab20028741550155411932280
   PubMed Web of Science ®Google Scholar
• Eghbali-FatourechiGKhoslaSSanyalABoyleWJLaceyDLRiggsBLRole of RANK ligand in mediating increased bone resorption in early postmenopausal womenJ Clin Invest200311181221123012697741
   PubMed Web of Science ®Google Scholar
• ChenQKajiHKanataniMSugimotoTChiharaKTestosterone increases osteoprotegerin mRNA expression in mouse osteoblast cellsHorm Metab Res2004361067467815523591
   PubMed Web of Science ®Google Scholar
• HofbauerLCHicokKCChenDKhoslaSRegulation of osteoprotegerin production by androgens and anti-androgens in human osteoblastic lineage cellsEur J Endocrinol2002147226927312153751
   PubMed Web of Science ®Google Scholar
• ProellVXuHSchulerCWeberKHofbauerLCErbenRGOrchiectomy upregulates free soluble RANKL in bone marrow of aged ratsBone200945467768119501680
   PubMed Web of Science ®Google Scholar
• LiXOminskyMSStolinaMIncreased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerinBone200945466967619539794
   PubMed Web of Science ®Google Scholar
• LeeSKLorenzoJAParathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formationEndocrinology199914083552356110433211
   PubMed Web of Science ®Google Scholar
• MaYLCainRLHalladayDLCatabolic effects of continuous human PTH 1–38 in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formationEndocrinology200114294047405411517184
   PubMed Web of Science ®Google Scholar
• SeckTDielIBismarHZieglerRPfeilschifterJSerum parathyroid hormone, but not menopausal status, is associated with the expression of osteoprotegerin and RANKL mRNA in human bone samplesEur J Endocrinol2001145219920511454517
   PubMed Web of Science ®Google Scholar
• KudlacekSSchneiderBWoloszczukWPietschmannPWillvonsederRAustrian Study Group on Normative Values of Bone MetabolismSerum levels of osteoprotegerin increase with age in a healthy adult populationBone200332668168612810175
   PubMed Web of Science ®Google Scholar
• PonchelFCuthbertRJGoëbVIL-7 and lymphopeniaClin Chim Acta2010915 [Epub ahead of print]
   Google Scholar
• CaoJJKurimotoPBoudignonBRosenCLimaFHalloranBPAging impairs IGF-I receptor activation and induces skeletal resistance to IGF-IJ Bone Miner Res20072281271127917488198
   PubMed Web of Science ®Google Scholar
• ZhaoHYLiuJMNingGRelationships between insulin-like growth factor-I (IGF-I) and OPG, RANKL, bone mineral density in healthy Chinese womenOsteoporos Int200819222122617703270
   PubMed Web of Science ®Google Scholar
• AkiyamaTDassCRShinodaYKawanoHTanakaSChoongPFPEDF regulates osteoclasts via osteoprotegerin and RANKLBiochem Biophys Res Commun2010391178979419945427
   PubMed Web of Science ®Google Scholar
• HsuYHNiuTTerwedowHAVariation in genes involved in the RANKL/RANK/OPG bone remodeling pathway are associated with bone mineral density at different skeletal sites in menHum Genet2006118556857716249885
   PubMed Web of Science ®Google Scholar
• RoshandelDHollidayKLPyeSRGenetic variation in the RANKL/RANK/OPG signaling pathway is associated with bone turnover and bone mineral density in menJ Bone Miner Res20102581830183820205168
   PubMed Web of Science ®Google Scholar
• CaoJVentonLSakataTHalloranBPExpression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 miceJ Bone Miner Res200318227027712568404
   PubMed Web of Science ®Google Scholar
• CaoJJWronskiTJIwaniecUAging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouseJ Bone Miner Res20052091659166816059637
   PubMed Web of Science ®Google Scholar
• MazziottiGAmatoGSorvilloFIncreased serum osteoprotegerin values in long-lived subjects: different effects of inflammation and bone metabolismEur J Endocrinol2006154337337716498049
   PubMed Web of Science ®Google Scholar
• PulsatelliLDolzaniPSilvestriTSoluble receptor activator of nuclear factor-kappaB ligand (sRANKL)/osteoprotegerin balance in ageing and age-associated diseasesBiogerontology20045211912715105586
   PubMed Web of Science ®Google Scholar
• NabipourILarijaniBVahdatKRelationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatoryMenopause200916595095519387415
   PubMed Web of Science ®Google Scholar
• HofbauerLCKhoslaSDunstanCRLaceyDLSpelsbergTCRiggsBLEstrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cellsEndocrinology199914094367437010465311
   PubMed Web of Science ®Google Scholar
• MichaelHHarkonenPLVaananenHKHentunenTAEstrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorptionJ Bone Miner Res200520122224223216294275
   PubMed Web of Science ®Google Scholar
• OhESRheeEJOhKWCirculating osteoprotegerin levels are associated with age, waist-to-hip ratio, serum total cholesterol, and low-density lipoprotein cholesterol levels in healthy Korean womenMetabolism2005541495415562379
   PubMed Web of Science ®Google Scholar
• Mezquita-RayaPde la HigueraMGarciaDFThe contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal womenOsteoporos Int200516111368137415711777
   PubMed Web of Science ®Google Scholar
• HanKOChoiJTChoiHAThe changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on boneClin Endocrinol (Oxf)200562334935315730418
   PubMed Web of Science ®Google Scholar
• WangYDWangLLiDJWangWJDehydroepiandrosterone inhibited the bone resorption through the upregulation of OPG/RANKLCell Mol Immunol200631414516549048
   PubMed Web of Science ®Google Scholar
• RogersASalehGHannonRAGreenfieldDEastellRCirculating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal womenJ Clin Endocrinol Metab200287104470447512364420
   PubMed Web of Science ®Google Scholar
• KhoslaSArrighiHMMeltonLJ3rdCorrelates of osteoprotegerin levels in women and menOsteoporos Int200213539439912086350
   PubMed Web of Science ®Google Scholar
• Fahrleitner-PammerADobnigHPiswanger-SoelknerCOsteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture statusWien Klin Wochenschr2003115929129712793029
   PubMed Web of Science ®Google Scholar
• IndridasonOSFranzsonLSigurdssonGSerum osteoprotegerin and its relationship with bone mineral density and markers of bone turnoverOsteoporos Int200516441742315776220
   PubMed Web of Science ®Google Scholar
• LiuJMZhaoHYNingGRelationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20–75Calcif Tissue Int20057611615455183
   PubMed Web of Science ®Google Scholar
• OhKWRheeEJLeeWYCirculating osteoprotegerin and receptor activator of NF-kappaB ligand system are associated with bone metabolism in middle-aged malesClin Endocrinol (Oxf)2005621929815638876
   PubMed Web of Science ®Google Scholar
• JorgensenLVikAEmausNBone loss in relation to serum levels of osteoprotegerin and nuclear factor-kappaB ligand: the Tromso studyOsteoporos Int201021693193819701599
   PubMed Web of Science ®Google Scholar
• ChibaYOnouchiTIkedaTAdachiJTamuraYHoriuchiTImplications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly womenGerontology200955327528019158438
   PubMed Web of Science ®Google Scholar
• SternALaughlinGABergstromJBarrett-ConnorEThe sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo studyEur J Endocrinol2007156555556217468191
   PubMed Web of Science ®Google Scholar
• JorgensenHLKuskPMadsenBFengerMLauritzenJBSerum osteoprotegerin (OPG) and the A163G polymorphism in the OPG promoter region are related to peripheral measures of bone mass and fracture odds ratiosJ Bone Miner Metab200422213213814999524
   PubMed Web of Science ®Google Scholar
• NakamichiYUdagawaNKobayashiYOsteoprotegerin reduces the serum level of receptor activator of NF-kappaB ligand derived from osteoblastsJ Immunol2007178119220017182555
   PubMed Web of Science ®Google Scholar
• UemuraHYasuiTMiyataniYCirculating profiles of osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand in post-menopausal womenJ Endocrinol Invest200831216316818362509
   PubMed Web of Science ®Google Scholar
• FindlayDChehadeMTsangariHCirculating RANKL is inversely related to RANKL mRNA levels in bone in osteoarthritic malesArthritis Res Ther2008101R218182105
   PubMed Web of Science ®Google Scholar
• SzulcPHofbauerLCHeufelderAERothSDelmasPDOsteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone statusJ Clin Endocrinol Metab20018673162316511443182
   PubMed Web of Science ®Google Scholar
• Gannage-YaredMHFaresFSemaanMKhalifeSJambartSCirculating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male populationClin Endocrinol (Oxf)200664665265816712667
   PubMed Web of Science ®Google Scholar
• KostenuikPJNguyenHQMcCabeJDenosumab, a fully human monoclonal antibody to RANKL inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKLJ Bone Miner Res200924218219519016581
   PubMed Web of Science ®Google Scholar
• BekkerPJHollowayDLRasmussenASA single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL in postmenopausal womenJ Bone Miner Res20041971059106615176987
   PubMed Web of Science ®Google Scholar
• McClungMRLewieckiEMCohenSBDenosumab in postmenopausal women with low bone mineral densityN Engl J Med2006354882183116495394
   PubMed Web of Science ®Google Scholar
• LewieckiEMMillerPDMcClungMRTwo-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMDJ Bone Miner Res200722121832184117708711
   PubMed Web of Science ®Google Scholar
• BoneHGBologneseMAYuenCKEffects of denosumab on bone mineral density and bone turnover in postmenopausal womenJ Clin Endocrinol Metab20089362149215718381571
   PubMed Web of Science ®Google Scholar
• CummingsSRSan MartinJMcClungMRDenosumab for prevention of fractures in postmenopausal women with osteoporosisN Engl J Med2009361875676519671655
   PubMed Web of Science ®Google Scholar
• GeusensPEmerging treatments for postmenopausal osteoporosis – focus on denosumabClin Interv Aging2009424125019554095
   PubMed Web of Science ®Google Scholar
• BeckTJLewieckiEMMillerPDEffects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronateJ Clin Densitom200811335135918495508
   PubMed Web of Science ®Google Scholar
• BrownJPPrinceRLDealCComparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trialJ Bone Miner Res200924115316118767928
   PubMed Web of Science ®Google Scholar
• LewieckiEMDenosumab–an emerging treatment for postmenopausal osteoporosisExpert Opin Biol Ther201010346747620095877
   PubMed Web of Science ®Google Scholar
• BrennanTCRybchynMSGreenWAtwaSConigraveADMasonRSOsteoblasts play key roles in the mechanisms of action of strontium ranelateBr J Pharmacol200915771291130019563530
   PubMed Web of Science ®Google Scholar
• CaudrillierAHurtel-LemaireASWattelAStrontium ranelate decreases receptor activator of nuclear factor-KB ligand-induced osteoclastic differentiation in vitro: involvement of the calcium sensing receptorMol Pharmacol201078456957620584969
   PubMed Web of Science ®Google Scholar
• AtkinsGJWelldonKJHalboutPFindlayDMStrontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin responseOsteoporos Int200920465366418763010
   PubMed Web of Science ®Google Scholar
• LewieckiEMCurrent and emerging pharmacologic therapies for the management of postmenopausal osteoporosisJ Womens Health (Larchmt)200918101615162619857095
   PubMed Web of Science ®Google Scholar
• MeunierPJSlosmanDODelmasPDStrontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis–a 2-year randomized placebo controlled trialJ Clin Endocrinol Metab20028752060206611994341
   PubMed Web of Science ®Google Scholar
• MeunierPJRouxCSeemanEThe effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosisN Engl J Med2004350545946814749454
   PubMed Web of Science ®Google Scholar